AnaptysBio (MEX:ANAB) Other Financing: MXN-1,201 Mil (TTM As of Mar. 2026)


MEX:ANAB AnaptysBio Inc MEX:ANAB
66 GF Score
Price MXN445.25
GF Value MXN428.61
! 5 Warning Signs
View Full Analysis

What is AnaptysBio Other Financing?

AnaptysBio MEX:ANAB 66 Other Financing is MXN-1,201 Mil as of Mar. 2026. GuruFocus rates MEX:ANAB with a GF Score™ of 66/100 and a GF Value™ of MXN428.61. The stock has 5 warning signs investors should review.

AnaptysBio's Other Financing for the three months ended in Mar. 2026 was MXN-231 Mil.

AnaptysBio's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-1,201 Mil.

AnaptysBio Other Financing Historical Data

* Premium members only.

The historical data trend for AnaptysBio's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio Other Financing Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,123.27 627.58 -199.77 556.18 -1,408.91

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -500.33 -15.50 -18.47 -935.61 -231.03
MEX:ANAB
66GF Score
AnaptysBio Inc MEX:ANAB
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,201 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN-1,201 Mil mean?
AnaptysBio (MEX:ANAB) has a Other Financing of MXN-1,201 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for AnaptysBio and its competitors.
Is AnaptysBio's Other Financing too high?
AnaptysBio's current Other Financing is MXN-1,201 Mil. Overall, AnaptysBio has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Other Financing compare to ABSI and TSHA?
AnaptysBio's Other Financing of MXN-1,201 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for AnaptysBio and its competitors. AnaptysBio's current Other Financing is MXN-1,201 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
AnaptysBio (MEX:ANAB) has a current Other Financing of MXN-1,201 Mil. The stock's GF Value™ is MXN428.61, compared to a current price of MXN445.25 — trading 3.9% above its estimated fair value. The current Other Financing is MXN-1,201 Mil. AnaptysBio's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For AnaptysBio (MEX:ANAB), the current Other Financing is MXN-1,201 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (MEX:ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of MXN445.25 is trading 3.9% above its estimated GF Value™ of MXN428.61.

Key valuation signals for MEX:ANAB:

  • Other Financing: MXN-1,201 Mil
  • GF Value™: MXN428.61 vs. price of MXN445.25 (3.9% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the MEX:ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges ANAB:USA0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for MEX:ANAB

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN445.25
Price
MXN428.61
GF Value